C-X-C Chemokine Receptor Type 4 (CXCR4) and Programmed Death-Ligand 1 (PD-L1) Expression are Prognostic Biomarkers for Papillary Thyroid Carcinoma

被引:0
|
作者
Ding, Ting [1 ]
Song, Qian [1 ]
Xu, Yanjun [2 ]
Liu, Qiya [3 ]
机构
[1] Huanggang Cent Hosp, Dept Endocrinol, Huanggang City 438021, Hubei, Peoples R China
[2] Zhejiang Univ Tradit Chinese Med, Dept Special Inspect Sect, Affiliated Hosp 3, Hangzhou 310014, Zhejiang, Peoples R China
[3] Sha He Hosp Chang Ping Dist Beijing, Dept Gen Med, Beijing 100005, Peoples R China
关键词
CXCR4; PD-L1; Papillary Thyroid Carcinoma; Survival Analysis; CANCER; SURVIVAL; NIVOLUMAB; ANTITUMOR; PATHWAY;
D O I
10.1166/jbt.2022.2987
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Chemokines and immunomodulatory factors involve in tumor development. Papillary thyroid carcinoma (PTC) is considered to start from dendritic cell infiltration and then produce immunomodulatory factors. In this study, CXCR4 and PD-L1 biomarkers were used to explore their prognostic role in PTC survival. Confocal microscopy detected the transfection efficiency in tumor cells. 42 PTC patients and thyroiditis patients (control) were enrolled to measure the expressions of CXCR4 and PD-L1. Multi-factor analysis analyzed the effect of combined CXCR4 and PD-L1 expression on ROC. The two groups had no differences in the baseline characteristics. CTXCR4 and PD-L1 level in PTC patients was significantly higher than control. CXCR4 was lowly expressed in thyroid cancer tissue and PD-L1 was highly expressed in serological samples. Compared with single measurement, the combined detection of CXCR4 and PD-L1 showed more ROC area. In conclusion, reduced CXCR4 and increased PD-L1 levelis found in thyroid cancer and their level might be used IP: 182.75.148.10 On: Thu, 20 Jan 2022 10:55:44 as predictive markers for PTtoCopyright:improve thAmeriancurative Scintificeffect. Publishers
引用
收藏
页码:953 / 957
页数:5
相关论文
共 50 条
  • [21] Programmed Death-Ligand 1 (PD-L1) Expression in Pheochromocytoma: Clinicopathologic Correlation
    Xiong, Meng-Jun
    Kissick, Haydn
    Master, Viraj
    Osunkoya, Adeboye O.
    MODERN PATHOLOGY, 2019, 32
  • [22] Programmed Cell Death-Ligand 1 (PD-L1) Expression in Anal Cancer
    Govindarajan, Rangaswamy
    Gujja, Swetha
    Siegel, Eric R.
    Batra, Anu
    Saeed, Anwaar
    Lai, Keith
    James, Jennifer D.
    Fogel, Bradley J.
    Williamson, Stephen
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (07): : 638 - 642
  • [23] Implementation of programmed death-ligand 1 (PD-L1) expression as a prognostic biomarker for patients with lung cancer
    Li, Huijuan
    Lin, Dang
    Lv, Tangfeng
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022,
  • [24] Rational Design of Conformationally Constrained Cyclopentapeptide Antagonists for C-X-C Chemokine Receptor 4 (CXCR4)
    Mungalpara, Jignesh
    Thiele, Stefanie
    Eriksen, Oystein
    Eksteen, Johann
    Rosenkilde, Mette M.
    Vabeno, Jon
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (22) : 10287 - 10291
  • [25] Expression pattern of immune checkpoints programmed death (PD-1) and programmed death-ligand (PD-L1) in retinoblastoma and its prognostic significance
    Singh, L.
    Kashyap, S.
    Pushker, N.
    Bakhshi, S.
    Sen, S.
    Rizvi, M. A.
    ANNALS OF ONCOLOGY, 2017, 28 : 11 - 11
  • [26] Programmed Death-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Expression in Aggressive Pediatric Lymphomas
    Coffey, Amy M.
    Curry, Jonathan L.
    Marcogliese, Andrea N.
    Tetzlaff, Michael T.
    Kamdar, Kala
    Elghetany, Mohamed T.
    Curry, Choladda V.
    LABORATORY INVESTIGATION, 2017, 97 : 344A - 344A
  • [27] Programmed Death-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) Expression in Aggressive Pediatric Lymphomas
    Coffey, Amy M.
    Curry, Jonathan L.
    Marcogliese, Andrea N.
    Tetzlaff, Michael T.
    Kamdar, Kala
    Elghetany, Mohamed T.
    Curry, Choladda V.
    MODERN PATHOLOGY, 2017, 30 : 344A - 344A
  • [28] Differential C-X-C Motif Chemokine Receptor 4 (CXCR4) Expression in Aldosterone Producing vs. Nonfunctional Adenomas
    Wu Chunyi
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [29] Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor
    Valentine Suteau
    Alexandre Collin
    Philippe Menei
    Patrice Rodien
    Marie-Christine Rousselet
    Claire Briet
    Cancer Immunology, Immunotherapy, 2020, 69 : 2053 - 2061
  • [30] Programmed death-ligand 1 (PD-L1) expression in small bowel adenocarcinomas (SBA)
    Pedersen, Katrina
    Smyrk, Thomas C.
    Harrington, Susan
    McWilliams, Robert R.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)